Related Experiment Video

Updated: Mar 23, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.6K

Optimum treatment of congenital cytomegalovirus infection

Marianne Leruez-Ville1,2, Yves Ville1,3

  • 1a EA 73-28, Université Paris Descartes, Sorbonne Paris Cité , Paris , France.

Expert Review of Anti-Infective Therapy
|April 5, 2016
PubMed

Insights

Congenital cytomegalovirus (CMV) infection, a leading cause of birth defects, lacks widespread screening. Emerging treatments for neonatal and prenatal congenital CMV infections suggest a proactive management approach is beneficial.

Area of Science:

  • Virology
  • Maternal-Fetal Medicine
  • Neonatology

Background:

  • Congenital cytomegalovirus (CMV) infection impacts 0.7% of live births, being the primary cause of infectious congenital neurological disabilities.
  • Despite its prevalence, systematic screening for congenital CMV during pregnancy or at birth is not globally implemented.
  • This lack of screening is attributed to the absence of an effective vaccine and limited data on congenital CMV treatment.

Purpose of the Study:

  • To review recent advancements in the management of congenital cytomegalovirus infections.
  • To update on the potential benefits of antiviral therapies and passive immunization strategies.
  • To evaluate the efficacy of both neonatal and antenatal treatment approaches for congenital CMV.

Main Methods:

  • Systematic literature review of recent studies on congenital cytomegalovirus (CMV) management.
  • Analysis of data on antiviral treatments and passive immunization in neonatal and antenatal periods.
  • Evaluation of emerging evidence for proactive management strategies.

Main Results:

  • Recent data highlight potential benefits of antiviral treatment for congenital CMV.
  • Passive immunization strategies show promise in both neonatal and antenatal contexts.
  • New findings support a proactive approach to managing congenital CMV infections.

Conclusions:

  • Emerging data suggest that antiviral treatment and passive immunization can offer benefits for congenital cytomegalovirus (CMV) infections.
  • A proactive management strategy for both neonatal and antenatal congenital CMV is increasingly supported by recent evidence.
  • Further research and implementation of screening and treatment protocols are warranted.

Keywords:
Cytomegaloviruscongenitalhyperimmmune globulinvalacyclovirvalganciclovir

More Related Videos

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

20.6K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.9K

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
7
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
612
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
539